{
    "nctId": "NCT02227992",
    "officialTitle": "A Prospective, Randomized, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST\u00ae Sealant Matrix in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic and Thoracic (Non-cardiac) Surgery in Paediatric Patients",
    "inclusionCriteria": "* Paediatric subjects aged \u226528 days (\u2265 1 month) to \\<18 years, requiring non-emergent open hepatic, abdominal, retroperitoneal, pelvic or thoracic (non-cardiac) surgical procedures. i) The first 36 subjects to be enrolled will be subjects aged \u22651 years to \\<18 years. ii) The next 4 subjects to be enrolled will be subjects aged \u226528 days to \\<1 year.\n* The subject's parent/legal guardian must be willing to give permission for the subject to participate in the trial, and provide written informed consent for the subject. In addition, assent must be obtained from paediatric subjects who possess the intellectual and emotional ability to comprehend the concepts involved in the trial. If the paediatric subject is not able to provide assent (due to age, maturity and/or inability to intellectually and/or emotionally comprehend the trial), the parent/legal guardian's written Informed Consent for the subject will be acceptable for the subject to be included in the study.\n* Presence of an appropriate mild or moderate bleeding soft tissue or hepatic parenchyma Target Bleeding Site (TBS) identified intra-operatively by the surgeon;\n* Ability to firmly press trial treatment at TBS until 4 minutes after randomisation\n* Must have minimum age of 28 Days\n* Must have maximum age of 17 Years",
    "exclusionCriteria": "* Subjects with known intolerance to blood products or to one of the components of the study product or is unwilling to receive blood products;\n* Female subjects, who are of childbearing age (i.e. adolescent), who are pregnant or nursing;\n* Subject is currently participating or plans to participate in any other investigational device or drug without prior approval from the Sponsor;\n* Subjects who are known, current alcohol and/or drug abusers\n* Subjects admitted for trauma surgery\n* Subjects with any pre or intra-operative findings identified by the surgeon that may preclude conduct of the study procedure.\n* Subject with TBS in an actively infected field (Class III Contaminated or Class IV Dirty or Infected)\n* TBS is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of the EVARREST\u2122 or SURGICEL\u00ae to blood flow and pressure during healing and absorption of the product;\n* TBS with major arterial bleeding requiring suture or mechanical ligation;\n* Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine."
}